1. Home
  2. ITOC vs XBIO Comparison

ITOC vs XBIO Comparison

Compare ITOC & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ITOC

iTonic Holdings Ltd Class A Ordinary Shares

N/A

Current Price

$0.28

Market Cap

5.0M

Sector

N/A

ML Signal

N/A

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

N/A

Current Price

$2.32

Market Cap

5.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ITOC
XBIO
Founded
1998
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
5.8M
IPO Year
2023
2011

Fundamental Metrics

Financial Performance
Metric
ITOC
XBIO
Price
$0.28
$2.32
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 745.8K
96.0K
Earning Date
03-20-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 38.52
EPS
★ N/A
N/A
Revenue
N/A
★ $2,976,411.00
Revenue This Year
N/A
$2.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 19.04
52 Week Low
$0.22
$1.90
52 Week High
$1.15
$13.93

Technical Indicators

Market Signals
Indicator
ITOC
XBIO
Relative Strength Index (RSI) 43.83 36.38
Support Level $0.27 $2.14
Resistance Level $0.36 $2.62
Average True Range (ATR) 0.04 0.30
MACD -0.00 -0.11
Stochastic Oscillator 8.76 8.49

Price Performance

Historical Comparison
ITOC
XBIO

About ITOC iTonic Holdings Ltd Class A Ordinary Shares

iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Share on Social Networks: